Sorafenib

Catalog No.S7397

Sorafenib is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM in cell-free assays, respectively.

Price Stock Quantity  
USD 147 In stock
USD 270 In stock
USD 670 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Sorafenib Chemical Structure

Sorafenib Chemical Structure
Molecular Weight: 464.82

Validation & Quality Control

Cited by 60 publications:

7 customer reviews :

Quality Control & MSDS

Related Compound Libraries

Sorafenib is available in the following compound libraries:

Product Information

  • Compare Raf Inhibitors
    Compare Raf Products
  • Research Area
  • Inhibition Profile

Product Description

Biological Activity

Description Sorafenib is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM in cell-free assays, respectively.
Targets Raf-1 [1]
(Cell-free assay)
mVEGFR2(Flk1) [1]
(Cell-free assay)
mVEGFR3 [1]
(Cell-free assay)
B-Raf [1]
(Cell-free assay)

 View  More

IC50 6 nM 15 nM 20 nM 22 nM
In vitro Sorafenib inhibits both wild-type and V599E mutant B-Raf activity with IC50 of 22 nM and 38 nM, respectively. Sorafenib also potently inhibits mVEGFR2 (Flk-1), mVEGFR3, mPDGFRβ, Flt3, and c-Kit with IC50 of 15 nM, 20 nM, 57 nM, 58 nM, and 68 nM, respectively. Sorafenib weakly inhibits FGFR-1 with IC50 of 580 nM. Sorafenib tosylate is not active against ERK-1, MEK-1, EGFR, HER-2, IGFR-1, c-Met, PKB, PKA, cdk1/cyclinB, PKCα, PKCγ, and pim-1. Sorafenib markedly inhibits VEGFR2 phosphorylation in NIH 3T3 cells with IC50 of 30 nM, and Flt-3 phosphorylation in HEK-293 cells with IC50 of 20 nM. Sorafenib potently blocks MEK 1/2 and ERK 1/2 phosphorylation in most cell lines but not in A549 or H460 cells, while having no effect on inhibition of the PKB pathway. Sorafenib inhibits the proliferation of HAoSMC and MDA-MB-231 cells with IC50 of 0.28 μM and 2.6 μM, respectively. [1] In addition to inhibition of the RAF/MEK/ERK signaling pathway, Sorafenib significantly inhibits the phosphorylation of eIF4E and down-regulates Mcl-1 levels in hepatocellular carcinoma (HCC) cells in a MEK/ERK-independent manner. Sorafenib inhibits the proliferation of PLC/PRF/5 and HepG2 cells with IC50 of 6.3 μM and 4.5 μM, respectively, and leads to the significant induction of apoptosis. [2]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
MV-4-11M17SdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{foe2lEPTB;MD6wNFAxODNyMzFOwG0>NXTlZVg1W0GQR1XS
MONO-MAC-6MmX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2XU[2lEPTB;MD6wNFQyQCEQvF2=MWPTRW5ITVJ?
ALL-POMV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVrJR|UxRTBwMEOxPFQh|ryPNUC2TWxLW0GQR1XS
NKM-1MlvLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M13Pe2lEPTB;MD6wO|QyPiEQvF2=NGW0WZdUSU6JRWK=
CGTH-W-1M1Xremdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUH0cY5ZUUN3ME2wMlI2ODJ{IN88US=>M4OwUXNCVkeHUh?=
BB65-RCCNIrpclFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGOxPXdKSzVyPUCuOFcxPzNizszNM4[xPXNCVkeHUh?=
NOS-1NV25ToZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHfwS4RKSzVyPUCuOVY{PiEQvF2=M1;pNXNCVkeHUh?=
SH-4MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmTWTWM2OD1yLk[1OlE{KM7:TR?=NXnxW|VFW0GQR1XS
HOP-62MnTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHTqbYtKSzVyPUCuPFUxQDhizszNM2PsR3NCVkeHUh?=
HCC2998NHz2UHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkHqTWM2OD1yLki4PFE5KM7:TR?=NGfB[2ZUSU6JRWK=
GDM-1NFixeVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVHJR|UxRTBwOUC2PVgh|ryPNFPrW49USU6JRWK=
KM12M2nLbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHTwOFdKSzVyPUGuNFIxQThizszNNGnTeXdUSU6JRWK=
LB2518-MELMXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnvaTWM2OD1zLkKwPFA6KM7:TR?=NIPzOZpUSU6JRWK=
NCI-H1436NY\ySplIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXnJR|UxRTFwMkG2O|gh|ryPMVfTRW5ITVJ?
EM-2M{m5Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MojQTWM2OD1zLkO1OVc5KM7:TR?=MX;TRW5ITVJ?
LAMA-84Ml;iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWrJR|UxRTFwM{e2OFgh|ryPMUnTRW5ITVJ?
KG-1NHvaXnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1PL[GlEPTB;MT60O|k{PSEQvF2=M3vjNXNCVkeHUh?=
A388NWrLS4hwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGPKVW1KSzVyPUGuOVkyPjVizszNMV;TRW5ITVJ?
no-10MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX\JR|UxRTFwNkG3NlYh|ryPM4CxfXNCVkeHUh?=
SF126NW\6WVF{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVPJR|UxRTFwNkO4NVIh|ryPNFH3[4pUSU6JRWK=
MEG-01MnziS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWnJR|UxRTFwOEC5PEDPxE1?MoHHV2FPT0WU
A3-KAWMXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4DnS2lEPTB;MT64PFQzKM7:TR?=NVHkO3N7W0GQR1XS
D-247MGM1qxeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV\JR|UxRTJwMUS0PEDPxE1?MUPTRW5ITVJ?
OVCAR-4NHy1UI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1e4[mlEPTB;Mj6yNVM6OyEQvF2=NUPHfJlFW0GQR1XS
NCI-SNU-1Ml7oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlfLTWM2OD1{LkOxOlIh|ryPNHzZellUSU6JRWK=
NCI-H2171M1nSdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGi4VGNKSzVyPUKuN|k4PjRizszNMlfNV2FPT0WU
SIG-M5NV[zeYdGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXfJR|UxRTJwNEKyOFIh|ryPMYTTRW5ITVJ?
BE-13Mmf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1naOmlEPTB;Mj62PVYxQSEQvF2=NYrrfoZxW0GQR1XS
K052NYH3[oxVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGWyXJFKSzVyPUKuO|Q3OTZizszNMUjTRW5ITVJ?
L-540M4rUc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX:1SlhLUUN3ME2yMlc2Pzh7IN88US=>NYjtT2hIW0GQR1XS
KMOE-2NWHseZZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn7ETWM2OD1{LkixN|Uh|ryPMWrTRW5ITVJ?
MFH-inoNUXFPHQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkPCTWM2OD1{LkmyNVg2KM7:TR?=MnvRV2FPT0WU
HL-60NFPJRZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mln1TWM2OD1|LkC2Nlk6KM7:TR?=NVrmfYU6W0GQR1XS
HCC2218MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{LRd2lEPTB;Mz6xNlAxOyEQvF2=Mn;DV2FPT0WU
TE-5NVm5TpdET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoHETWM2OD1|LkGzNVYzKM7:TR?=NGLpVolUSU6JRWK=
MZ1-PCM1jMfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUftUXg5UUN3ME2zMlQ4PTB7IN88US=>NGe5XGxUSU6JRWK=
MRK-nu-1M{i0SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVvJR|UxRTNwNkG0Olgh|ryPMYHTRW5ITVJ?
MZ7-melM2fiOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWSzdpRmUUN3ME2zMlY3ODl7IN88US=>MoLOV2FPT0WU
BC-1M33ZcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{i0Z2lEPTB;Mz63OFAzKM7:TR?=MoLvV2FPT0WU
ST486NVjKO25tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn76TWM2OD1|LkizOlc{KM7:TR?=NX3Ye|doW0GQR1XS
KS-1M4q0[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4jQdmlEPTB;Mz64PFE6QCEQvF2=NUfVZ5E{W0GQR1XS
SK-NEP-1MnjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkPTTWM2OD12LkG2PFE2KM7:TR?=NXLwZppqW0GQR1XS
BC-3M{KzSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnTITWM2OD12LkKzN|kyKM7:TR?=MoizV2FPT0WU
NCI-H1581MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1:2cWlEPTB;ND6yPFc6QCEQvF2=MYXTRW5ITVJ?
MHH-PREB-1M3K3WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEGyZZFKSzVyPUSuOFA1QDRizszNM4q2cnNCVkeHUh?=
NOMO-1MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUPJR|UxRTRwNEi5NFUh|ryPMmPOV2FPT0WU
QIMR-WILM4O1Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1;RR2lEPTB;NT6wO|I6PCEQvF2=NHvUUZJUSU6JRWK=
SF539MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M321cWlEPTB;NT6xN|IzPyEQvF2=NIXjXGpUSU6JRWK=
TE-12MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIK1NHpKSzVyPUWuNlQ6OjlizszNNHvCfoZUSU6JRWK=
NCI-H510AMXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2PZUWlEPTB;NT60NVY5PSEQvF2=NHTXOZRUSU6JRWK=
JARM1PmZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmjuTWM2OD13LkWwPFI1KM7:TR?=M{m2V3NCVkeHUh?=
no-11NELIdpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUTJR|UxRTVwN{O1Olgh|ryPM{HIeXNCVkeHUh?=
BV-173NUnhNYt1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHjGO|lKSzVyPUWuPVU3QDJizszNMXzTRW5ITVJ?
SRNH7uVJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHzR[4VKSzVyPU[uNFA3PzhizszNM2TEZnNCVkeHUh?=
MOLT-16NVfzPYlRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXLyc|dTUUN3ME22MlI2OjZ4IN88US=>M1HkSXNCVkeHUh?=
MZ2-MELMXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnTITWM2OD14LkOxPFM6KM7:TR?=NXq2fFQ4W0GQR1XS
SW954MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NY\VWmxrUUN3ME22MlQ2QDZ4IN88US=>Mor2V2FPT0WU
ML-2MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3LkWGlEPTB;Nj61Nlg1QSEQvF2=M1jNfHNCVkeHUh?=
OCI-AML2NX7mfI5QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NI[ySJVKSzVyPU[uOlExPjJizszNMX3TRW5ITVJ?
SIMANX;PfGZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVvJR|UxRTdwMECxNFEh|ryPMkLDV2FPT0WU
DOHH-2NVvoc4VOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUPJR|UxRTdwMEW2O|Yh|ryPNHXCN|hUSU6JRWK=
697MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIr0b3FKSzVyPUeuNFU6QDlizszNNEHKVnlUSU6JRWK=
NB1MmLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWHJR|UxRTdwNEC0NFch|ryPMnGxV2FPT0WU
D-392MGMULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUjSNWpuUUN3ME23MlYzPjZ|IN88US=>MnjsV2FPT0WU
ES8NESwfGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEfFeoVKSzVyPUeuO|Y2ODNizszNMoTnV2FPT0WU
RPMI-8226NIjzfG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1TKbmlEPTB;Nz64OFUyOSEQvF2=MWXTRW5ITVJ?
IST-MEL1NUD0[Y9YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MonQTWM2OD16LkSwNFAzKM7:TR?=MVTTRW5ITVJ?
NB14NI\BW2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEnYfGZKSzVyPUiuOlMyOzNizszNM{fDd3NCVkeHUh?=
HD-MY-ZMWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV[4V2FLUUN3ME24MlY{PzR4IN88US=>M12zd3NCVkeHUh?=
TE-10Ml31S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{\KXGlEPTB;OD63OlM2OyEQvF2=MUHTRW5ITVJ?
LC-1FM2jOUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MonsTWM2OD17LkGwPFM1KM7:TR?=NYr2OW1nW0GQR1XS
OS-RC-2MlXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2\0UmlEPTB;OT6xNVI1OyEQvF2=M1XkW3NCVkeHUh?=
NCI-SNU-16NYD2SmhbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWjOVpZlUUN3ME25MlIyODJ4IN88US=>MmDmV2FPT0WU
SHP-77NGrLNotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoS1TWM2OD17LkexOlYzKM7:TR?=M2Xn[nNCVkeHUh?=
A4-FukMXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVHJR|UxRTlwN{W2NUDPxE1?NFqyTnNUSU6JRWK=
NB6MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M17qVWlEPTB;OT63OlAzQSEQvF2=MU\TRW5ITVJ?
JiyoyeP-2003MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVfJR|UxRTFyLkS3OFUh|ryPMknpV2FPT0WU
DMS-114MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkXNTWM2OD1zMD61OFQyKM7:TR?=MoT2V2FPT0WU
NB7NUfYZ2NFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEHyWmRKSzVyPUGwMlc2OjZizszNMV\TRW5ITVJ?
NCI-H747MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYDGbGdQUUN3ME2xNU4yOjF4IN88US=>MoHWV2FPT0WU
HHMXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWrJR|UxRTFzLkO4O|Yh|ryPMYrTRW5ITVJ?
EW-18M{TwV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmW2TWM2OD1zMT65NFQ1KM7:TR?=M4H4eXNCVkeHUh?=
CHP-126NVK5bVNVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{ezfmlEPTB;MUGuPVc{QCEQvF2=MXHTRW5ITVJ?
NTERA-S-cl-D1NFHqXIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHjqOFZKSzVyPUGyMlAzPzhizszNMXXTRW5ITVJ?
DELMU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXPZfIpCUUN3ME2xNk4xQTh3IN88US=>NXfmZZJuW0GQR1XS
LU-139MlvWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVnJR|UxRTF{LkW0NVMh|ryPMknCV2FPT0WU
P30-OHKNFSxeW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3jkVWlEPTB;MUKuOVQ4QSEQvF2=MlHvV2FPT0WU
NCI-H1522NUm0XIk3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX;JR|UxRTF{Lke0OkDPxE1?NYq0OIlmW0GQR1XS
NCI-H1299M3jUXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVjqcVlWUUN3ME2xN{4zQTFzIN88US=>MXvTRW5ITVJ?
UACC-257NHzoT4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4X4[mlEPTB;MUOuOVEzPiEQvF2=M3i1UXNCVkeHUh?=
Calu-6NVPlflduT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWHFZ|h[UUN3ME2xN{43ODR4IN88US=>NXTJbGZNW0GQR1XS
NCI-H1882Mlj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWDJR|UxRTF|Lki1OVUh|ryPNYfweJM3W0GQR1XS
BB30-HNCM2rSdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFHuW4NKSzVyPUG0MlA3ODlizszNNXS2bVdHW0GQR1XS
ES1MmHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV3vTGRDUUN3ME2xOE4yPTVzIN88US=>MlXFV2FPT0WU
NCI-H1694M1H6cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mnm5TWM2OD1zND60PFEyKM7:TR?=NGfTUGlUSU6JRWK=
IST-SL1NF\WXJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1Tqc2lEPTB;MUSuPVYyPiEQvF2=NUK5cnBMW0GQR1XS
ECC4MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3Tv[GlEPTB;MUWuNFU2QCEQvF2=M{\WNHNCVkeHUh?=
MDA-MB-134-VIMlKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGfnc2VKSzVyPUG1MlQyOzFizszNMYHTRW5ITVJ?
SCHMlm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXrJR|UxRTF3LkS3Nlgh|ryPMWjTRW5ITVJ?
SK-N-FIMnf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MY\JR|UxRTF3Lk[1N|Qh|ryPNHTRRXRUSU6JRWK=
HDLM-2MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml3kTWM2OD1zNj6wO|E1KM7:TR?=M{HZWXNCVkeHUh?=
Ramos-2G6-4C10NGLjVlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NI\zWJVKSzVyPUG2MlEzQTdizszNMn3uV2FPT0WU
EW-24Mm\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHj6TIJKSzVyPUG2MlE3PjFizszNNH73e4hUSU6JRWK=
NCI-H2141MnK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVzJR|UxRTF4LkG4PUDPxE1?NXr0VmVbW0GQR1XS
LC4-1NImybYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mmm4TWM2OD1zNj62NVE6KM7:TR?=M4XEUHNCVkeHUh?=
HT-144MnvaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4XlZWlEPTB;MUeuNFA3KM7:TR?=MWTTRW5ITVJ?
SK-MEL-1NWGwVlFsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml[zTWM2OD1zNz6wNFczKM7:TR?=MYDTRW5ITVJ?
SCC-15NGKyS21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2\sfmlEPTB;MUeuNVY{QCEQvF2=MlHzV2FPT0WU
C8166Mn\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NULQVod2UUN3ME2xO{43QDN|IN88US=>Mk\qV2FPT0WU
GOTOMnTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXq2[XVYUUN3ME2xO{45OzR2IN88US=>M4DwbHNCVkeHUh?=
COR-L279NFXqPG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYe3ZVR4UUN3ME2xPE4yOzZ{IN88US=>M2PKeHNCVkeHUh?=
K-562Ml;jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NE\ze|BKSzVyPUG4MlcyPDNizszNNYmxNG1HW0GQR1XS
ES3M2\D[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGjjeo9KSzVyPUG4MlgxPDFizszNNWLDN4N2W0GQR1XS
LU-165NFT1Z|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVnJR|UxRTF7LkewNFgh|ryPM4HQS3NCVkeHUh?=
KM-H2NGD5SGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnjmTWM2OD1{MD6zNVg1KM7:TR?=NY\5d3lyW0GQR1XS
RLNXTRW2tDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUXJR|UxRTJyLkm2PVIh|ryPMWDTRW5ITVJ?
EW-3NXzOPYN{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mk\ETWM2OD1{MT6xPFg6KM7:TR?=NHjLUlZUSU6JRWK=
A101DM4Cwc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1LMe2lEPTB;MkGuN|c2OiEQvF2=MnPGV2FPT0WU
HUTU-80M1;BTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlrGTWM2OD1{MT6zPVQ3KM7:TR?=NEfQb29USU6JRWK=
NCI-H23NIrYd|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnzITWM2OD1{MT6zPVkzKM7:TR?=NHXHdGZUSU6JRWK=
PF-382MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmfETWM2OD1{MT60OFA{KM7:TR?=M4T4eHNCVkeHUh?=
LB373-MEL-DNFuxUlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlTnTWM2OD1{MT61OlE2KM7:TR?=M3ruNHNCVkeHUh?=
TE-8NHPlR2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWjJR|UxRTJzLk[zPVQh|ryPNGTpUGhUSU6JRWK=
TE-9M{XMNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYKwNINmUUN3ME2yNU45PTF|IN88US=>NGK4dnNUSU6JRWK=
DaudiNUCwe5BzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmnHTWM2OD1{MT65N|A1KM7:TR?=NGD1UXRUSU6JRWK=
D-542MGNGLUSWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGnMdnRKSzVyPUKyMlAzPTZizszNMUHTRW5ITVJ?
U-698-MMniyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV36cVV6UUN3ME2yNk41PjB|IN88US=>MXXTRW5ITVJ?
ES6Mkm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWfJR|UxRTJ{LkezOlYh|ryPNWDyPXRkW0GQR1XS
DU-4475MoOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{PXPGlEPTB;MkOuPFg6PyEQvF2=M1LNe3NCVkeHUh?=
ECC12M1q5R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYjCbW1HUUN3ME2yOE4zQDB|IN88US=>MknOV2FPT0WU
C2BBe1MoXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1uyUmlEPTB;MkSuN|I{QSEQvF2=NFnIb|dUSU6JRWK=
IST-SL2NHSzUZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3PxcWlEPTB;MkSuOFM3OiEQvF2=NVjaN5U1W0GQR1XS
DJM-1MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYXQd2hpUUN3ME2yOE42OjJzIN88US=>M4exU3NCVkeHUh?=
DMS-153NH3o[JVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MonVTWM2OD1{ND64OlE1KM7:TR?=M2roW3NCVkeHUh?=
NB13MlHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUnJR|UxRTJ3LkCyOlUh|ryPMl;UV2FPT0WU
SK-N-DZNXfZcJZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVTJR|UxRTJ4LkO0NVQh|ryPNEC1N3NUSU6JRWK=
COR-L88MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MojTTWM2OD1{Nj61O|k3KM7:TR?=MXTTRW5ITVJ?
LU-65NEXBNFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{jNXGlEPTB;Mk[uPFU{PSEQvF2=MXfTRW5ITVJ?
TGBC1TKBM3XzSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2m2[mlEPTB;Mk[uPVgzQCEQvF2=MnPmV2FPT0WU
THP-1MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHTtb|RKSzVyPUK3MlIyPDFizszNNWfwOoE3W0GQR1XS
ONS-76NGK5NpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEC4VZRKSzVyPUK3MlM{OiEQvF2=Mny1V2FPT0WU
LC-2-adNX7FU2M4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUKxfWxSUUN3ME2yO{43OjNzIN88US=>NIfDXlNUSU6JRWK=
EW-13MmXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVT1TJRvUUN3ME2yPU4yPzR4IN88US=>M1;BbXNCVkeHUh?=
MS-1NXnTdXFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M17HOWlEPTB;M{CuO|I4QCEQvF2=Mn;wV2FPT0WU
NCI-H2227M{H0e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mm\lTWM2OD1|MD65PFA3KM7:TR?=M1jVdXNCVkeHUh?=
LXF-289NVX3V4lmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFW4e2JKSzVyPUOxMlQ1QTJizszNNUHtPWNsW0GQR1XS
MC116MojwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVK0TYlrUUN3ME2zNk4xQDJ4IN88US=>M4fmRXNCVkeHUh?=
EVSA-TNEn2NmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUjJR|UxRTN{LkK1PFUh|ryPMmLrV2FPT0WU
CTB-1NIjCXnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXzJTXVRUUN3ME2zN{4yOTBzIN88US=>MojpV2FPT0WU
COLO-320-HSRNYDTSFRVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NY\SfoVLUUN3ME2zN{4yPjB|IN88US=>M2rFeHNCVkeHUh?=
NCI-H2196MnXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXzQdYl5UUN3ME2zN{4zPTV5IN88US=>NXXJSHBQW0GQR1XS
LB2241-RCCMYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml33TWM2OD1|Mz6zNVM2KM7:TR?=NFLQW|hUSU6JRWK=
LS-513MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MliwTWM2OD1|Mz64OlM5KM7:TR?=NHjl[pJUSU6JRWK=
LP-1NUjCVIUzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXHuVnNCUUN3ME2zN{46QTV4IN88US=>NXzZPYZ2W0GQR1XS
A253NGTD[I5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoK4TWM2OD1|ND6yNlk3KM7:TR?=MnzWV2FPT0WU
SK-MM-2M2fxcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml3CTWM2OD1|ND65OFUyKM7:TR?=MofHV2FPT0WU
NCI-H1963MlvtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWfnR4hNUUN3ME2zOU4{ODd{IN88US=>NVHFV5Z4W0GQR1XS
MMAC-SFMon4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml7OTWM2OD1|NT64O|g2KM7:TR?=MV;TRW5ITVJ?
LB831-BLCMoGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlfMTWM2OD1|Nj6wOlU1KM7:TR?=NYrKVnMzW0GQR1XS
WSU-NHLMnvGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYrJR|UxRTN4LkG2OEDPxE1?NFj4RnhUSU6JRWK=
CESSMojNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmnCTWM2OD1|Nj6yPFQ5KM7:TR?=MoGzV2FPT0WU
NEC8MmPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHGzOFBKSzVyPUO2MlU5OzVizszNNVnYSm9iW0GQR1XS
KNS-42M4jCdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEXW[JhKSzVyPUO3MlEzOzdizszNMV7TRW5ITVJ?
MHH-CALL-2NIi1UYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NE\kcZBKSzVyPUO3MlE5OjFizszNNWC2foxmW0GQR1XS
K5MnnUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFfDXJRKSzVyPUO4MlQ{KM7:TR?=M3TTe3NCVkeHUh?=
CP66-MELM1fEUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3fhS2lEPTB;M{muNFc{OyEQvF2=MXjTRW5ITVJ?
OPM-2NHfRZ5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlG5TWM2OD1|OT64OFMzKM7:TR?=MkHPV2FPT0WU
IST-MES1MlTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{XKdmlEPTB;NECuN|A6PiEQvF2=MX7TRW5ITVJ?
EC-GI-10MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXzJR|UxRTRzLkW4NFUh|ryPNXnBVIFxW0GQR1XS
CTV-1MmDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MorMTWM2OD12Mj64OFA3KM7:TR?=NEDMW29USU6JRWK=
DG-75M3rtXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYDPcIl4UUN3ME20N{44PTl3IN88US=>M{jvSnNCVkeHUh?=
KNS-81-FDMWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkTwTWM2OD12NT60NFU5KM7:TR?=M1P3bnNCVkeHUh?=
NCI-H82MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnW4TWM2OD12NT61O|U5KM7:TR?=NIqxZ3pUSU6JRWK=
RPMI-8866MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{jlSWlEPTB;NE[uNVg4OyEQvF2=M1mzZXNCVkeHUh?=
ACNNWqwb4JkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnT5TWM2OD12Nj60N|Qh|ryPM4PBSHNCVkeHUh?=
NCI-H1395NV\wWJd{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYPJR|UxRTR4LkS3OVYh|ryPNEjldnlUSU6JRWK=
NCI-H209NVjIZWJvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mor3TWM2OD12Nz6xOFA2KM7:TR?=NE\y[YZUSU6JRWK=
TGWMX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHr2b|RKSzVyPUS5MlA4QTFizszNM3zxenNCVkeHUh?=
NCI-H748NWjlTFk{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVrJR|UxRTR7LkS3OVMh|ryPM2C4WHNCVkeHUh?=
EKVXNHrvUnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV3LTJN6UUN3ME20PU43PjJ6IN88US=>MULTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo Oral administration of Sorafenib (~60 mg/kg) demonstrates broad spectrum, dose-dependent anti-tumor activity against a variety of human tumor xenograft models including MDA-MB-231, Colo-205, HT-29, DLD-1, NCI-H460, and A549, with no evidence of toxicity. In association with the anti-tumor efficacy, Sorafenib treatment potently inhibits MEK 1/2 phosphorylation and pERK 1/2 levels in HT-29 and MDA-MB-231 xenografts but not in Colo-205 xenografts, and significantly suppresses tumor microvessel area (MVA) and microvessel density (MVD) in MDA MB-231, HT-29 and Colo-205 tumor xenografts. [1] Sorafenib treatment produces dose-dependent growth inhibition of PLC/PRF/5 tumor xenografts in SCID mice with TGIs of 49% and 78% at 10 mg/kg and 30 mg/kg, respectively, consistent with the inhibition of ERK and eIF4E phosphorylation, reduction of the microvessel area, and induction of tumor cell apoptosis. [2] Sorafenib sensitizes bax-/- cells to TRAIL in a dose-dependent manner, through a mechanism involving down-regulating NF-κB mediated Mcl-1 and cIAP2 expression. Combining Sorafenib (30-60 mg/kg) with TRAIL (5 mg/kg) show dramatic efficacy in TRAIL-resistant HCT116 bax-/- and HT29 tumor xenografts. [3]
Features

Protocol(Only for Reference)

Kinase Assay:

[1]

Biochemical assays Recombinant baculoviruses expressing Raf-1 (residues 305–648) and B-Raf (residues 409–765) are purified as fusion proteins. Full-length human MEK-1 is generated by PCR and purified as a fusion protein from Escherichia coli lysates. Sorafenib tosylate is added to a mixture of Raf-1 (80 ng), or B-Raf (80 ng) with MEK-1 (1 μg) in assay buffer [20 mM Tris (pH 8.2), 100 mM NaCl, 5 mM MgCl2, and 0.15% β-mercaptoethanol] at a final concentration of 1% DMSO. The Raf kinase assay (final volume of 50 μL) is initiated by adding 25 μL of 10 μM γ[33P]ATP (400 Ci/mol) and incubated at 32 °C for 25 minutes. Phosphorylated MEK-1 is harvested by filtration onto a phosphocellulose mat, and 1% phosphoric acid is used to wash away unbound radioactivity. After drying by microwave heating, a β-plate counter is used to quantify filter-bound radioactivity. Human VEGFR2 (KDR) kinase domain is expressed and purified from Sf9 lysates. Time-resolved fluorescence energy transfer assays for VEGFR2 are performed in 96-well opaque plates in the time-resolved fluorescence energy transfer format. Final reaction conditions are as follows: 1 to 10 μM ATP, 25 nM poly GT-biotin, 2 nM Europium-labeled phospho (p)-Tyr antibody (PY20), 10 nM APC, 1 to 7 nM cytoplasmic kinase domain in final concentrations of 1% DMSO, 50 mM HEPES (pH 7.5), 10 mM MgCl2, 0.1 mM EDTA, 0.015% Brij-35, 0.1 mg/mL BSA, and 0.1% β-mercaptoethanol. Reaction volumes are 100 μL and are initiated by addition of enzyme. Plates are read at both 615 and 665 nM on a Perkin-Elmer VictorV Multilabel counter at ~1.5 to 2.0 hours after reaction initiation. Signal is calculated as a ratio: (665 nm/615 nM) × 10,000 for each well. For IC50 generation, Sorafenib tosylate is added before the enzyme initiation. A 50-fold stock plate is made with Sorafenib tosylate serially diluted 1:3 in a 50% DMSO/50% distilled water solution. Final Sorafenib tosylate concentrations range from 10 μM to 4.56 nM in 1% DMSO.

Cell Assay:

[1]

Cell lines MDA-MB-231, and HAoSMC
Concentrations Dissolved in DMSO, final concentrations ~10 μM
Incubation Time 72 hours
Method

Cells are exposed to increasing concentrations of Sorafenib tosylate for 72 hours. Cell number is quantitated using the Cell TiterGlo ATP Luminescent assay kit. This assay measures the number of viable cells per well by measurement of luminescent signal based on amount of cellular ATP.

Animal Study:

[1]

Animal Models Female NCr-nu/nu mice implanted s.c. with MDA-MB-231, Colo-205, HT-29, H460, or A549 cells
Formulation Dissolved in Cremophor EL/ethanol (50:50) as 4-fold (4 × stock solution, and diluted to 1 × with water
Dosages ~60 mg/kg
Administration Orally once daily

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Wilhelm SM, et al. Cancer Res, 2004, 64(19), 7099-7109.

[2] Liu L, et al. Cancer Res, 2006, 66(24), 11851-11858.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-07-30)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02834546 Not yet recruiting Hepatocellular Carcinoma (HCC) University Hospital, Bordeaux September 2016 --
NCT02836847 Recruiting Cholangiocarcinoma of the Extrahepatic Bile Duct|Gallbladder Cancer Shanghai Jiao Tong University School of Medicine|Xinhua H  ...more Shanghai Jiao Tong University School of Medicine|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|Ruijin Hospital|RenJi Hospital|Eastern Hepatobiliary Surgery Hospital|Huashan Hospital July 2016 Phase 2
NCT02575339 Recruiting Hepatocellular Carcinoma|Liver Cancer|HCC Bert ONeil, MD|Hoosier Cancer Research Network|Millennium  ...more Bert ONeil, MD|Hoosier Cancer Research Network|Millennium Pharmaceuticals, Inc.|Big Ten Cancer Research Consortium July 2016 Phase 1|Phase 2
NCT02747537 Not yet recruiting Pediatric Solid Tumors Washington University School of Medicine July 2016 Phase 2
NCT02774187 Recruiting Hepatocellular Carcinoma Sun Yat-sen University May 2016 Phase 3

view more

Chemical Information

Download Sorafenib SDF
Molecular Weight (MW) 464.82
Formula

C21H16ClF3N4O3

CAS No. 284461-73-0
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms BAY 43-9006
Solubility (25°C) * In vitro DMSO 63 mg/mL warming (135.53 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Raf Products

  • LY3009120

    LY03009120 is a potent pan-Raf inhibitor with IC50 of 44 nM, 31-47 nM, and 42 nM for A-raf, B-Raf, and C-Raf in A375 cells, respectively. Phase 1.

  • GDC-0994

    GDC-0994 is a potent, orally available ERK1/2 inhibitor with IC50 of 1.1 nM and 0.3 nM, respectively. Phase 1.

  • Ulixertinib (BVD-523, VRT752271)

    Ulixertinib (BVD-523, VRT752271) is a potent and reversible ERK1/ERK2 inhibitor with IC50 of <0.3 nM for ERK2. Phase 1.

  • Vemurafenib (PLX4032, RG7204)

    Vemurafenib (PLX4032, RG7204) is a novel and potent inhibitor of B-RafV600E with IC50 of 31 nM in cell-free assay.

    Features:A novel and potent inhibitor of the B-RAFV600E oncoprotein.

  • Dabrafenib (GSK2118436)

    Dabrafenib (GSK2118436) is a mutant BRAFV600 specific inhibitor with IC50 of 0.8 nM in cell-free assays, with 4- and 6-fold less potency against B-Raf(wt) and c-Raf, respectively.

  • Sorafenib Tosylate

    Sorafenib Tosylate is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM in cell-free assays, respectively.

  • PLX-4720

    PLX4720 is a potent and selective inhibitor of B-RafV600E with IC50 of 13 nM in a cell-free assay, equally potent to c-Raf-1(Y340D and Y341D mutations), 10-fold selectivity for B-RafV600E than wild-type B-Raf.

  • TAK-632

    TAK-632 is a potent pan-Raf inhibitor with IC50 of 8.3 nM and 1.4 nM for B-Raf(wt) and C-Raf in cell-free assays, respectively, showing less or no inhibition against other tested kinases.

  • GDC-0879

    GDC-0879 is a novel, potent, and selective B-Raf inhibitor with IC50 of 0.13 nM in A375 and Colo205 cells with activity against c-Raf as well; no inhibition known to other protein kinases.

  • GW5074

    GW5074 is a potent and selective c-Raf inhibitor with IC50 of 9 nM, no effect on the activities of JNK1/2/3, MEK1, MKK6/7, CDK1/2, c-Src, p38 MAP, VEGFR2 or c-Fms is noted.

Recently Viewed Items

Tags: buy Sorafenib | Sorafenib supplier | purchase Sorafenib | Sorafenib cost | Sorafenib manufacturer | order Sorafenib | Sorafenib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us